Comment on “Updates in Clinical Management of Recurrent Urinary Tract Infections”

One of the most common bacterial infections is urinary tract infection (UTI), with an annual incidence estimated at 150 million globally. In the United States, 10. 5 million office visits, up to 3 million emergency department visits, and 3. 5 billion annually can be attributed to UTI. Due to this high incidence and the elevated lifetime risk of UTI, clinicians must be well-informed about treatment options and best practices, especially in the context of recurrent UTIs and asymptomatic bacteriuria. This article summarizes updates to the guidelines surrounding the diagnosis and management of recurrent UTI. Recurrent UTI is defined as 2 or more separate UTIs within 1 year. The pathophysiology of recurrent UTI has been poorly characterized in the past, but recent evidence has shown that it has to do with the microbiome of the bladder and vagina. Changes in this microbiota due to hormonal changes and menopause can increase the risk of recurrent UTI. Dysuria is a specific symptom of UTI for young women, but is less predictive in older individuals. For perimenopausal and postmenopausal women, diagnosis based on symptoms can be inaccurate due to overlap with other conditions. To improve diagnostic accuracy, guidelines have been updated to recommend obtaining urinary diagnostic testing for each symptomatic episode before treatment initiation for recurrent UTI. This can include a urine dipstick, a standard urine culture, microscopic urinalysis, enhanced urine culture, or culture-independent testing. For acute treatment, there are no reliable ways to predict which patients will need antibiotics and which will not; increasing rates of resistance to antimicrobial agents and antibiotics have contributed to an interest in nonantibiotic alternatives for both acute and recurrent UTI cases. There is a gap in the literature surrounding this aspect of UTI treatment, and thus a pressing need for prospective studies about which patients can heal without antibiotics and which should have more targeted treatment. Treatment methods can consist of a culture-directed approach (delaying therapy until culture results are received), nonsteroidal anti-inflammatory drugs, and antibiotic treatment (including new antibiotics such as pivmecillinam, sulopenem etzadroxil with probenecid, and gepotidacin), all of which carry their own risks and benefits. Recommendations for prevention focus on low-dose prophylaxis for recurrent UTIs, with re-evaluation every few months due to the potential for antimicrobial resistance. Review of the literature surrounding nonantibiotic agents for the prevention of recurrent UTI showed that most nonantibiotic agents are not as effective at prevention. As yet, there is little evidence surrounding various combinations of nonantibiotic agents, so research is again needed to assess this as a potential alternative to antibiotics. In perimenopausal and postmenopausal women, vaginal estrogen therapy can be recommended to prevent recurrent episodes of UTI. Other potential methods of nonantibiotic treatment and/or prevention of recurrent UTI include probiotics, D -Mannose, cranberry, and methenamine Hippurate, but as yet none have strong evidence to support their efficacy. New therapies being studied for UTI prevention in recurrent cases include immune-modulating UTI vaccines and bacteriophage therapies. (Summarized from Siddiqui NY, Bradley MS. Updates in clinical management of recurrent urinary tract infections. Obstet Gynecol. 2025;146: 631-644. doi: 10. 1097/AOG. 0000000000006060)